<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="165">
  <stage>Registered</stage>
  <submitdate>10/08/2005</submitdate>
  <approvaldate>15/08/2005</approvaldate>
  <actrnumber>ACTRN12605000150640</actrnumber>
  <trial_identification>
    <studytitle>Is regional anaesthesia associated with postoperative cognitive deficit? A prospective randomised controlled trial.</studytitle>
    <scientifictitle>The prospective randomised controlled phase III GRAIL Trial will consider patients receiving general anaesthesia compared to those receiving regional anaesthesia to undergo extracorporeal shock wave lithotripsy for the treatment of kidney stones and will evaluate whether there is any difference in the incidence of postoperative cognitive dysfunction (POCD) in the short and medium term.</scientifictitle>
    <utrn />
    <trialacronym>The GRAIL Trial</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Post Operative Cognitive Dysfunction (POCD)</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Studies of normal psychology, cognitive function and behaviour</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To study patients undergoing a single surgical treatment: extracorporeal shock wave lithotripsy (ESWL) for treatment of kidney stones. General anaesthesia will consist of routine clinical practice using midazolam/fentanyl/propofol/laryngeal mask/spontaneous respiration of air and oxygen. Regional anaesthesia will conform to current practice consisting of #25 gauge spinal needle and 0.5% heavy spinal marcaine. Patients will complete a neuropyschological test battery preoperatively, 7 days and 3 months postoperatively and a short test version at discharge.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Freqeuncy of POCD</outcome>
      <timepoint>At 7 days and 3 months postoperatively.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>At 3 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients who are scheduled for elective ESWL, do not have neurological deficit, give written informed consent and have no contraindication to neuropsychological testing. The patients must reside in accessible proximity to the hospital to enable investigators to administer testing at home. </inclusivecriteria>
    <inclusiveminage>55</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Pre-existing neurological or neurovascualr disease (eg. stroke); 2. Score of less than 24 on the Mini Mental State Examination (MMSE); 3. Anticipated difficulty with neuropsychologcail assessment such as English not being the prime language, blindness, deafness; 4. Associated medical problems that may lead to significant complications and subsequent loss to follow-up (ASA Physical Status IV or higher); 5. Contraindication to spinal anaesthesia (eg. anti-coagulation therapy or bleeding tendency); 6. Body Mass Index (BMI) greater than 35.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed envelope to anaesthetist immediately prior to procedure.</concealment>
    <sequence>Random allocation sequence will be generated by computer software PC_PLAN. The restriction method will be random permuted blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>7/11/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr. Brendan Silbert</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Australia and New Zealand College of Anaesthetists</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>A/Prof. David Scott</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>A/Prof. Paul Maruff</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Ms. Lis Evered</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St. Vincent's Hospital Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ms. Lis Evered</name>
      <address>Department of Anaesthesia
St. Vincent's Hospital
PO Box 2900
Fitzroy VIC 3065</address>
      <phone>+61 3 92882251</phone>
      <fax>+61 3 92884255</fax>
      <email>everedl@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Brendan Silbert</name>
      <address>Department of Anaesthesia
St. Vincent's Hospital
PO Box 2900
Fitzroy VIC 3065</address>
      <phone>+61 3 92884253</phone>
      <fax>+61 3 92884255</fax>
      <email>silberbs@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>